ProCE Banner Activity

The Evolving Role of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Bladder Cancer: Downloadable Slides

Slideset Download
Download slides with key data on the optimal use of immune checkpoint inhibitors for bladder cancer and strategies for multidisciplinary care to optimize patient outcomes.

Released: August 22, 2018

Expiration: August 21, 2019

No longer available for credit.

Share

Faculty

David Y. T. Chen

David Y. T. Chen, MD, FACS

Associate Professor, Urologic Oncology
Department of Surgical Oncology
Director, Urologic Oncology Fellowhip
Fox Chase Cancer Center-Temple Health
Philadelphia, Pennsylvania

Alexander Kutikov

Alexander Kutikov, MD, FACS

Chief of Urology and Urologic Oncology
Professor of Urologic Oncology
Department of Surgical Oncology
Fox Chase Cancer Center
Temple University Health System
Philadelphia, Pennsylvania

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck Oncology

Faculty Disclosure

Primary Author

David Y. T. Chen, MD, FACS

Associate Professor, Urologic Oncology
Department of Surgical Oncology
Director, Urologic Oncology Fellowhip
Fox Chase Cancer Center-Temple Health
Philadelphia, Pennsylvania

Alexander Kutikov, MD, FACS

Chief of Urology and Urologic Oncology
Professor of Urologic Oncology
Department of Surgical Oncology
Fox Chase Cancer Center
Temple University Health System
Philadelphia, Pennsylvania

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania